English (UK)
中文版
Dr Lihua Zheng
AnHeart Therapeutics is an oncology-focused clinical stage biopharmaceutical company headquartered in Hangzhou, China with offices in Beijing, Shanghai and New York. The company’s pipeline consists of three clinical stage assets: Taletrectinib, a next-gen ROS1 and NTRK inhibitor currently in Phase 2; an mIDH1 inhibitor ready for Phase 2 for low grade glioma, cholangiocarcinoma, AML and other tumors; and an AXL inhibitor in Phase 1 for overcoming resistance in various tumors.
AnHeart Therapeutics
CBO & co-Founder
Linda Zheng
A French PHARMA & cosmetics company
Pierre Fabre Medicament China
Senior Market Access & Health Economics DirectorMin Zhou
Hainan Haiyao, a Chinese public company with stock code of 000566, is established in 1965, mainly focused on some severe diseases such as infection, tumor, digestion system etc.
Hainan Haiyao Co. , Ltd
BD DirectorIvy Zhou
Shenzhen Beimei Pharma is focused in the field of pediatric prescription drugs, and aims to become a new-styled pharmaceutical company integrated with R&D, in-licensing, production and sales. It takes independent R&D and the in-licensing of domestic and international pediatric products as its strategic direction. The current product pipeline covers the respiratory, anti-infection (antibacterial), neuroscience, gastroenterology and others. Beimei Pharma is committed to providing Chinese pediatric patients with convenient, accurate, excellent-taste and high-quality products.
Shenzhen Beimei Pharmaceutical Co. Ltd.
Head of Business DevelopmentMonica Zhou
Established in Shenzhen Special Economic Zone in 1992;
Core competitiveness - A specialty company in digestion and intestinal microecology and a national level Hi-tech Enterprise.
Core competitiveness - A specialty company in digestion and intestinal microecology and a national level Hi-tech Enterprise.
Responsive Web Design powered by 